CO5180579A1 - Composicion oral solida que comprende levidopa, carbidopa y entacapone - Google Patents

Composicion oral solida que comprende levidopa, carbidopa y entacapone

Info

Publication number
CO5180579A1
CO5180579A1 CO00048944A CO00048944A CO5180579A1 CO 5180579 A1 CO5180579 A1 CO 5180579A1 CO 00048944 A CO00048944 A CO 00048944A CO 00048944 A CO00048944 A CO 00048944A CO 5180579 A1 CO5180579 A1 CO 5180579A1
Authority
CO
Colombia
Prior art keywords
entacapone
carbidopa
solid oral
oral composition
levidopa
Prior art date
Application number
CO00048944A
Other languages
English (en)
Inventor
Matti Virkki
Vakervou Kari
Ritalia Marja
Partanen Marja
Niskanen Mervi
Lintulaakso Jarmo
Laaksonen Marja
Kervinen Lasse
Kallioinen Sari
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5180579(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of CO5180579A1 publication Critical patent/CO5180579A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

La presente invención se relaciona con una composición farmacéutica, en especial con una composición sólida oral, que comprende cantidades farmacéuticamente efectivas de entacapone, levodopa y carbidopa o de sus sales o hidratos farmacéuticamente aceptables y un excipiente farmacéuticamente aceptable, en donde el excipiente es un alcohol de azúcar o almidón o un alcohol de azúcar y almidón. El entacapone, la levodopa y la carbidopa son útiles para tratar el mal de Parkinson.
CO00048944A 1999-06-30 2000-06-29 Composicion oral solida que comprende levidopa, carbidopa y entacapone CO5180579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus

Publications (1)

Publication Number Publication Date
CO5180579A1 true CO5180579A1 (es) 2002-07-30

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00048944A CO5180579A1 (es) 1999-06-30 2000-06-29 Composicion oral solida que comprende levidopa, carbidopa y entacapone

Country Status (42)

Country Link
US (2) US6500867B1 (es)
EP (1) EP1189608B1 (es)
JP (2) JP4204783B2 (es)
KR (1) KR100905428B1 (es)
CN (1) CN1168440C (es)
AR (1) AR033796A1 (es)
AT (1) ATE245417T1 (es)
AU (1) AU765932B2 (es)
BG (1) BG65364B1 (es)
BR (2) BR0011867A (es)
CA (1) CA2378469C (es)
CO (1) CO5180579A1 (es)
CZ (2) CZ304416B6 (es)
DE (1) DE60004052T2 (es)
DK (1) DK1189608T3 (es)
EA (1) EA004503B1 (es)
EE (1) EE05473B1 (es)
ES (1) ES2203495T3 (es)
FI (1) FI109453B (es)
FR (1) FR2797587A1 (es)
GE (1) GEP20043314B (es)
HK (1) HK1047040B (es)
HR (1) HRP20020088B1 (es)
HU (1) HU230395B1 (es)
IL (1) IL146807A (es)
IT (1) ITMI20001450A1 (es)
ME (1) ME00520B (es)
MX (1) MXPA01013167A (es)
MY (1) MY127685A (es)
NO (2) NO330260B1 (es)
NZ (1) NZ515780A (es)
PE (1) PE20010399A1 (es)
PL (1) PL197818B1 (es)
PT (1) PT1189608E (es)
RS (1) RS50368B (es)
SI (1) SI1189608T1 (es)
SK (1) SK286451B6 (es)
TR (1) TR200103763T2 (es)
TW (1) TWI241187B (es)
UA (1) UA75047C2 (es)
WO (1) WO2001001984A1 (es)
ZA (1) ZA200109868B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
US20040180086A1 (en) * 2002-10-11 2004-09-16 Zebunnissa Ramtoola Gastro-retentive levodopa delivery form
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
EP1812070B1 (en) 2004-11-10 2013-10-02 Orion Corporation Treatment of restless legs syndrome
EA013161B1 (ru) * 2005-06-08 2010-02-26 Орион Корпорейшн Дозированная форма для перорального применения
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
SI1907382T1 (sl) 2005-07-26 2015-10-30 Bial-Portela & Ca S.A., Nitrokateholni derivati kot inhibitorji COMT
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
US20090012170A1 (en) * 2005-09-21 2009-01-08 Helena Nissinen Treatment of symptoms of motor dysfunction
EP1945188A2 (en) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa compositions
EP1954256A2 (en) * 2005-11-09 2008-08-13 Torrent Pharmaceuticals Ltd Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
EP2063867A2 (en) * 2006-12-22 2009-06-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
LT2481410T (lt) 2007-01-31 2016-11-10 Bial - Portela & Ca., S.A. Nitrokatecholio dariniai kaip komt inhibitoriai vartojami konkrečiu dozavimo režimu
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
AU2009211030B2 (en) * 2008-02-06 2013-12-05 Wockhardt Research Centre Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
EP2252284B1 (en) * 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
JP2011514380A (ja) 2008-03-17 2011-05-06 バイアル−ポルテラ アンド シーエー，エス．エー． ５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形
US20110229566A1 (en) * 2008-08-22 2011-09-22 Yatendra Kumar Gupta Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof
KR101667762B1 (ko) * 2008-08-22 2016-10-20 욱크하르트 리미티드 엔타카폰 또는 이의 염의 서방형 약학 조성물
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
PT3192500T (pt) * 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
US9750702B2 (en) 2009-12-25 2017-09-05 Innopharmax, Inc. Pharmaceutical composition for treating parkinson's disease and preparation method thereof
EA026419B1 (ru) * 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
DE102010023828A1 (de) 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
SG10201509316SA (en) * 2010-11-15 2015-12-30 Neuroderm Ltd Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
BR112013027219A2 (pt) * 2011-04-26 2016-12-27 Innopharmax Inc composição de entacapone, processo para preparar a composição de entacapone, composição farmacêutica, e, uso da composição de entacapone
JP6456143B2 (ja) 2011-12-13 2019-01-23 ノヴィファーマ，エス．アー． カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
DK2854764T3 (en) 2012-06-05 2019-04-08 Neuroderm Ltd COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF
BR112015022390A8 (pt) * 2013-03-13 2019-11-26 Neuroderm Ltd uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
CA2926082C (en) 2013-10-07 2022-06-14 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2967693T3 (es) 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP4356907A1 (en) * 2014-09-04 2024-04-24 LobSor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
EP3236957A1 (en) 2014-12-23 2017-11-01 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2018011181A1 (en) * 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
EP3500246B1 (en) 2016-08-18 2021-08-04 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Antiparkinson tablet formulation with improved dissolution profile
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
AU2019237857A1 (en) 2018-03-23 2020-10-08 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
ZA200109868B (en) 2003-05-28
DK1189608T3 (da) 2003-11-10
MXPA01013167A (es) 2002-07-02
HRP20020088B1 (en) 2007-05-31
CZ304416B6 (cs) 2014-04-23
IL146807A (en) 2006-10-05
BR0011867A (pt) 2002-03-05
DE60004052T2 (de) 2004-04-15
ITMI20001450A0 (it) 2000-06-28
YU92501A (sh) 2004-09-03
AR033796A1 (es) 2004-01-07
EE05473B1 (et) 2011-10-17
JP2008156373A (ja) 2008-07-10
NO330260B1 (no) 2011-03-14
CA2378469C (en) 2009-10-06
AU765932B2 (en) 2003-10-02
HK1047040A1 (en) 2003-02-07
PE20010399A1 (es) 2001-04-10
WO2001001984A1 (en) 2001-01-11
GEP20043314B (en) 2004-02-10
SI1189608T1 (en) 2004-04-30
JP4204783B2 (ja) 2009-01-07
SK286451B6 (sk) 2008-10-07
PL352775A1 (en) 2003-09-08
US6797732B2 (en) 2004-09-28
DE60004052D1 (de) 2003-08-28
EP1189608A1 (en) 2002-03-27
CN1168440C (zh) 2004-09-29
HUP0202273A3 (en) 2002-11-28
CA2378469A1 (en) 2001-01-11
HK1047040B (zh) 2005-04-29
PT1189608E (pt) 2003-12-31
BG65364B1 (bg) 2008-04-30
NZ515780A (en) 2004-06-25
RS50368B (sr) 2009-11-10
EP1189608B1 (en) 2003-07-23
ITMI20001450A1 (it) 2001-12-28
US6500867B1 (en) 2002-12-31
EA200200106A1 (ru) 2002-06-27
NO20016203L (no) 2002-02-25
SK19232001A3 (sk) 2002-06-04
NO20110090L (no) 2002-02-25
ME00520B (me) 2011-10-10
FI991485A (fi) 2000-12-31
EE200100716A (et) 2003-02-17
KR100905428B1 (ko) 2009-06-30
MY127685A (en) 2006-12-29
HRP20020088A2 (en) 2005-10-31
BRPI0011867B8 (pt) 2021-05-25
TR200103763T2 (tr) 2002-04-22
ES2203495T3 (es) 2004-04-16
ATE245417T1 (de) 2003-08-15
CN1358090A (zh) 2002-07-10
BRPI0011867B1 (pt) 2019-01-08
FR2797587A1 (fr) 2001-02-23
BG106251A (en) 2002-08-30
KR20020010155A (ko) 2002-02-02
TWI241187B (en) 2005-10-11
JP2003503454A (ja) 2003-01-28
EA004503B1 (ru) 2004-04-29
NO20016203D0 (no) 2001-12-18
HUP0202273A2 (en) 2002-10-28
CZ303010B6 (cs) 2012-02-29
UA75047C2 (en) 2006-03-15
PL197818B1 (pl) 2008-04-30
AU5830600A (en) 2001-01-22
FI991485A0 (fi) 1999-06-30
HU230395B1 (hu) 2016-04-28
CZ20014636A3 (cs) 2002-05-15
JP4885896B2 (ja) 2012-02-29
US20030017201A1 (en) 2003-01-23
FI109453B (fi) 2002-08-15

Similar Documents

Publication Publication Date Title
CO5180579A1 (es) Composicion oral solida que comprende levidopa, carbidopa y entacapone
ECSP024399A (es) Derivados de benzotiazol
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
HN1998000113A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
MX9206851A (es) Sales organicas de n,n'-diacetil cistina, proceso para su preparacion y composicion farmaceutica que las contiene.
BR0010555A (pt) Inibidores de neuraminidases
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
BR9611015A (pt) Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto
ES2190674T3 (es) Uso de n-alquil derivados de cadena larga de desoxinojirimicina para la fabricacion de un medicamento para el tratamiento de enfermedades de acumulacion de glucolipidos.
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
BR9807876A (pt) Compostos heterocìclicos e seu uso para inibição de peptìdeo beta-amilóide
AR098997A2 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
ES2194202T3 (es) Compuestos polimorfos.
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
CO4950550A1 (es) Procedimiento
ECSP003546A (es) Una nueva composicion farmaceutica
DE69828522D1 (de) Antithrombotische mittel
HUP0004667A2 (hu) Új, optikailag aktív aminopentán-származékok
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.

Legal Events

Date Code Title Description
FG Application granted